Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

[Kidney function in oncologic patients after cisplastin chemotherapy].

Hozhenko AI, Moskalenko OM, Sirman VM, ZhiZhnievs'ka OO, Storozhenko SA.

Fiziol Zh. 2012;58(3):72-6. Ukrainian.

PMID:
22946315
2.

A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.

Leu L, Baribeault D.

J Oncol Pharm Pract. 2010 Sep;16(3):167-71. doi: 10.1177/1078155209346071. Epub 2009 Sep 16.

PMID:
19759050
3.

[Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].

Losonczy G, Máthé C, Müller V, Szondy K, Moldvay J.

Magy Onkol. 2010 Dec;54(4):289-96. doi: 10.1556/MOnkol.54.2010.4.3. Hungarian.

4.

Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.

Hartmann JT, Fels LM, Franzke A, Knop S, Renn M, Maess B, Panagiotou P, Lampe H, Kanz L, Stolte H, Bokemeyer C.

Anticancer Res. 2000 Sep-Oct;20(5C):3767-73.

PMID:
11268452
5.

Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.

Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV.

Cancer Chemother Pharmacol. 2003 Jul;52(1):13-8. Epub 2003 Apr 29.

PMID:
12719883
6.

Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.

Rajkumar SV, Frytak S, Rubin J, Camoriano JK, Fitch TR.

Am J Clin Oncol. 1997 Oct;20(5):500-4.

PMID:
9345336
7.

Renal tubular function in patients treated with high-dose cisplatin.

Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP.

Clin Pharmacol Ther. 1988 Aug;44(2):164-72.

PMID:
2840230
8.

Tubular dysfunction after peritonectomy and chemohyperthermic treatment with cisplatin.

La Manna G, Virzì S, Deraco M, Capelli I, Accorsi A, Dalmastri V, Comai G, Bonomi S, Grassi A, Selva S, Feliciangeli G, Scolari M, Stefoni S.

In Vivo. 2006 Nov-Dec;20(6A):703-6.

9.

Functional studies on the immediate polyuria after human renal transplantation.

Leme CE, Ribeiro CA Jr, Silva HB.

Rev Bras Pesqui Med Biol. 1975 Jan-Feb;8(1):45-52. No abstract available.

PMID:
1098115
10.

Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.

Erdlenbruch B, Nier M, Kern W, Hiddemann W, Pekrun A, Lakomek M.

Eur J Clin Pharmacol. 2001 Aug;57(5):393-402.

PMID:
11599657
11.

Cisplatin-induced vomiting depends on circadian timing.

Kobayashi M, To H, Tokue A, Fujimura A, Kobayashi E.

Chronobiol Int. 2001 Sep;18(5):851-63.

PMID:
11763992
12.

Renal tolerance to cisplatin in patients 70 years and older.

Cubillo A, Cornide M, López JL, Molina R, Feliu J, Espinosa E, Zamora P, de Castro J, Ordoñez A, González Barón M.

Am J Clin Oncol. 2001 Apr;24(2):192-7.

PMID:
11319297
13.

Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.

Koch Nogueira PC, Hadj-Aïssa A, Schell M, Dubourg L, Brunat-Mentigny M, Cochat P.

Pediatr Nephrol. 1998 Sep;12(7):572-5.

PMID:
9761357
14.

Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation.

Caglar K, Kinalp C, Arpaci F, Turan M, Saglam K, Ozturk B, Komurcu S, Yavuz I, Yenicesu M, Ozet A, Vural A.

Nephrol Dial Transplant. 2002 Nov;17(11):1931-5.

PMID:
12401849
15.

Cisplatin dose rate as a risk factor for nephrotoxicity in children.

Skinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW.

Br J Cancer. 1998 May;77(10):1677-82.

16.

Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.

Cornelison TL, Reed E.

Gynecol Oncol. 1993 Aug;50(2):147-58. Review.

PMID:
8375728
17.

Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.

Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, Ohno T, Masuhara K, Tanaka Y, Kato K, Nagai H, Yokoyama A, Kurita Y.

Cancer Chemother Pharmacol. 1996;39(1-2):131-7.

PMID:
8995510
18.

[Cisplatin nephrotoxicity: effects on fractional excretion of sodium and enzymuria].

Cirami C, Bianchi AM, Galigani P, Gadducci A, Colombi L, Facchini V, Palla R.

Minerva Med. 1990 Jan-Feb;81(1-2):79-86. Italian.

PMID:
1969127
19.

[Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].

Soejima A, Inoue T, Suzuki M, Waku M, Nakabayashi K, Kitamoto K, Nagasawa T.

Nihon Jinzo Gakkai Shi. 1992 Jul;34(7):801-6. Japanese.

PMID:
1479719
20.

Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus.

Johnsson A, Höglund P, Grubb A, Cavallin-Ståhl E.

Cancer Chemother Pharmacol. 1996;39(1-2):25-33.

PMID:
8995496

Supplemental Content

Support Center